UTI Vaccine Could Sidestep Antibiotics, But Might Not Help Everyone
A new oral UTI vaccine is being hailed as a “game changer”—but is it the cure we need?
Overactive urinary bladder in a female, 3D illustration. A condition where there is a frequent feeling of needing to urinate, sometimes with loss of bladder control leading to urge incontinence
A UK study has introduced a new approach to preventing urinary tract infections (UTIs), revealing that a twice-daily dose of a pineapple-flavored vaccine, MV140, taken under the tongue for three months, could ward off UTIs for up to nine years in many cases.
While the findings introduce a new method for managing recurrent UTIs, the debate continues over the need for a vaccine, given the range of existing treatments for this common health issue.
MV140: New Vaccine Challenges UTI Treatment Norm
Urinary tract infections, the most common bacterial infections globally, affect more than half of women and a considerable number of men. They are responsible for over 8 million physician visits annually in the United States, incurring costs of approximately $1.6 billion.
Sheramy Tsai
Author
Sheramy Tsai, BSN, RN, is a seasoned nurse with a decade-long writing career. An alum of Middlebury College and Johns Hopkins, Tsai combines her writing and nursing expertise to deliver impactful content. Living in Vermont, she balances her professional life with sustainable living and raising three children.
